Pre-made Roledumab benchmark antibody ( Whole mAb, anti-RHD therapeutic antibody, Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Roledumab biosimilar, Whole mAb, Anti-RHD Antibody: Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-490-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Roledumab biosimilar, Whole mAb, Anti-RHD Antibody: Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI therapeutic antibody
INN Name	Roledumab
Target	RHD
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II/III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	LFB Biotechnologies
Conditions Approved	na
Conditions Active	Haemolytic disease of newborn
Conditions Discontinued	na
Development Tech	EMABling Platform